COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Benefits of PDT more far-reaching than previously expected

March 1, 2003

Article

Orlando-Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics) is used widely to treat predominantly classic choroidal neovascularization (CNV) in age-related macular degeneration (AMD). The therapy, however, has met clinician resistance for treating occult CNV despite good visual results in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study and the Verteporfin in Photodynamic Therapy (VIP) Trial, according to Joan W. Miller, MD.